4,876 results match your criteria: "Tardive Dyskinesia"

Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-head clinical trials, management of VMAT2i in the clinical setting may be unclear and rely on the clinical experience of the practitioner.

View Article and Find Full Text PDF

Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.

Neurotox Res

December 2024

Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Chronic use of typical antipsychotics can lead to varying motor effects depending on the timing of analysis. Acute treatment typically induces hypokinesia, resembling parkinsonism, while repeated use can result in tardive dyskinesia, a hyperkinetic syndrome marked by involuntary orofacial movements, such as vacuous chewing movements in mice. Tardive dyskinesia is particularly concerning due to its potential irreversibility and associated motor discomfort.

View Article and Find Full Text PDF

Tardive Dyskinesia (TD) can occur in people exposed to dopamine receptor antagonists (DRAs). Its clinical management remains challenging. We conducted a systematic review/random-effects network meta-analysis (NMA) searching PubMed/MEDLINE/PsycINFO/ClinicalTrials.

View Article and Find Full Text PDF

We report the case of a 23-year-old man who developed orofacial dyskinesia secondary to aripiprazole whilst being treated for psychosis in the hospital. He was known to mental health services and had suffered a relapse of bipolar affective disorder. Upon cessation of aripiprazole and commencement of quetiapine, there was a rapid reversal of his movement disorder.

View Article and Find Full Text PDF

Effects of Acute Haloperidol Treatment on Dopaminergic Markers, GAD and A Receptors in Rats with High and Low VCMs.

Neurochem Res

November 2024

Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica, Universidade Federal de Santa Maria, RS, Brazil.

Vacuous chewing movements (VCM) have been utilized as an experimental model of orofacial dyskinesia (OD) in rodents to study the underlying molecular mechanisms related to tardive dyskinesia (TD). This study aimed to investigate if the acute treatment with haloperidol can alter components of the dopaminergic synapse or its modulators such as glutamic acid decarboxylase (GAD) and adenosine 2A (A) receptor. Furthermore, to evaluate if changes in molecular markers are associated with the number of VCMs induced by haloperidol in rats it is proposing a method to classify the animals into High and Low VCM groups.

View Article and Find Full Text PDF

Clavulanic acid (ClvA), a beta-lactamase inhibitor, is being explored for its significant neuroprotective potential. The effects of ClvA were assessed both individually and in combination with crocin (Cr), an antioxidant derived from saffron, in the context of tardive dyskinesia (TD). In rat haloperidol (Hp)-induced-TD (1 mg/kg, i.

View Article and Find Full Text PDF

Background And Objective: Inadequate response to antidepressant monotherapy is common among patients with major depressive disorder (MDD). The efficacy and safety of adjunctive brexpiprazole 2 mg/day has recently been confirmed during the 6-week, randomized, placebo-controlled phase 2/3 (BLESS) study, which evaluated brexpiprazole at 1 mg/day and 2 mg/day versus placebo as adjunctive therapy to antidepressant therapies in 740 Japanese patients with MDD and an inadequate response to antidepressant monotherapy. This study evaluated the long-term safety and efficacy of adjunctive fixed-dose brexpiprazole 2 mg/day in Japanese patients with MDD.

View Article and Find Full Text PDF
Article Synopsis
  • Tardive dyskinesia and dystonia are persistent movement disorders caused by antipsychotic medications blocking dopamine receptors.
  • Treatments like valbenazine and botulinum toxin have shown some effectiveness, but their overall success is still not completely proven.
  • A case study is presented of a woman with bipolar disorder and treatment-resistant symptoms who improved after undergoing electroconvulsive therapy, along with a review of existing literature on its safety and efficacy for these conditions.
View Article and Find Full Text PDF
Article Synopsis
  • - The review focuses on deutetrabenazine's effectiveness in managing chorea, a major motor symptom of Huntington's disease (HD), which is a neurodegenerative disorder with no known cure.
  • - Deutetrabenazine, the first FDA-approved treatment for HD-related chorea, works by reducing the release of dopamine and other monoamines, potentially improving patients' quality of life.
  • - While deutetrabenazine shows promise, more research is needed to fully assess its effectiveness and advantages, especially given the mixed results from current studies.
View Article and Find Full Text PDF

Background And Objectives: In 2017, the FDA approved deutetrabenazine (AUSTEDO) for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). Concurrently, valbenazine (INGREZZA) was approved specifically for TD. The adoption of new medications is influenced by various factors, including patient's medical needs, the prescriber's adoption of new practice, and external environmental factors (e.

View Article and Find Full Text PDF
Article Synopsis
  • Lumateperone, approved by the FDA for treating schizophrenia in adults since 2019, lacks sufficient real-world data on adverse reactions, prompting a study on adverse events (AEs) linked to the drug and their risk factors.
  • The analysis examined 2,644 reports of AEs related to Lumateperone from the FDA Adverse Event Reporting System, revealing 739 were classified as severe, with dizziness as the most common severe AE and tardive dyskinesia showing the highest risk signal.
  • Logistic regression identified gender, bipolar II disorder, and concomitant drug use as key independent risk factors for severe AEs, with female patients having a notably higher risk compared to males.
View Article and Find Full Text PDF

Background: Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.

Methods: We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3-8 weeks) that enrolled adults with schizophrenia.

View Article and Find Full Text PDF

Antipsychotic medications, while crucial in managing severe psychiatric disorders such as schizophrenia and bipolar disorder, are frequently associated with extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). TD, characterized by repetitive, involuntary movements, especially of the face and limbs, poses a substantial clinical challenge due to its often irreversible nature. Conventional management strategies, including dose reduction and switching to atypical antipsychotics, frequently offer limited success, prompting exploration of alternative therapies.

View Article and Find Full Text PDF

Vitexin (VTX), a C-glycosylated flavone found in various medicinal herbs, is known for its antioxidant, anti-inflammatory, and neuroprotective properties. This study investigated the protective effects of VTX against orofacial dyskinesia (OD) in rats, induced by haloperidol (HPD), along with the neuroprotective mechanisms underlying these effects. OD was induced by administering HPD (1 mg/kg i.

View Article and Find Full Text PDF
Article Synopsis
  • The study looked at how effective clozapine is for treating tardive syndromes, which are problems that can happen after taking certain medications for a long time.
  • Most of the patients in the study had issues like muscle spasms or uncontrolled movements when they started using clozapine.
  • After treatment, many patients saw a big improvement, with some having their symptoms completely go away!
View Article and Find Full Text PDF

Stress fracture of the first rib is a rare but an important cause of brachial plexopathy. Here, we describe a patient with a unilateral brachial plexus injury presenting with involuntary neck movements. A 22-year-old man with cervical involuntary movements for 10 months was diagnosed with tardive dyskinesia.

View Article and Find Full Text PDF

Researchers have used elements of administrative healthcare claims data (e.g., diagnosis codes and medications) to calculate rates of extrapyramidal symptoms (EPS) in patients with schizophrenia who utilize second-generation antipsychotics (SGAs).

View Article and Find Full Text PDF

Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements, most commonly affecting the face, tongue, and extremities. It is primarily associated with the long-term use of first-generation (typical) antipsychotics but can also occur with second-generation (atypical) antipsychotics such as aripiprazole. Despite its lower risk profile, aripiprazole can induce TD, as illustrated by a 45-year-old woman with schizophrenia who developed severe involuntary movements after five years of stable treatment with this medication.

View Article and Find Full Text PDF

Vertical rhythmic dyskinetic movements that are primarily drug-induced and affect solely the jaw, mouth, and lips without involving the tongue have been historically described as "rabbit" syndrome (RS). Evidence on the unique features and implications of this disorder remains limited. This literature review aims to evaluate the clinical-epidemiological profile, pathological mechanisms, and management of this movement disorder.

View Article and Find Full Text PDF

Chronic Cocaine Use and Parkinson's Disease: An Interpretative Model.

Int J Environ Res Public Health

August 2024

VP Dole Research Group, G. De Lisio Institute of Behavioural Sciences, Via di Pratale 3, 56121 Pisa, Italy.

Article Synopsis
  • Cocaine use has become a significant public health issue, with roughly 24.6 million users globally and 1 million diagnosed with cocaine use disorder, according to the 2023 World Drug Report.
  • While short-term effects of cocaine are well-documented, there is a lack of comprehensive data on its medium and long-term impacts, which suggest increased risks for cardiovascular issues and neurodegenerative diseases.
  • The paper proposes that chronic cocaine use leads to neurobiological changes affecting neurotransmitter systems, particularly dopaminergic pathways, which may increase vulnerability to neurodegenerative disorders and highlights the need for further research to inform therapeutic interventions.
View Article and Find Full Text PDF
Article Synopsis
  • Pisa syndrome, also known as pleurothotonus, is a neurological condition causing a noticeable lateral curvature of the spine when standing, often linked to certain medications.
  • A systematic review identified 109 articles detailing 191 cases of drug-induced Pisa syndrome, showing a prevalence ranging from 0.037 to 9.3%, primarily affecting females around the age of 59.70 years.
  • The review suggested new diagnostic criteria for Pisa syndrome and indicated that various mechanisms might contribute to balance control and the development of the condition.
View Article and Find Full Text PDF